Semax & Selank

Semax + Selank Nasal Spray is supplied as a catalogued research material in the following format and strength: nasal spray blend, Semax 10mg + Selank 10mg per 10ml (10mg/10mg/10ml). This is a two-compound formulation; effects of the combination are not established.

Semax is the ACTH(4–7)-Pro-Gly-Pro heptapeptide with the sequence MEHFPGP. Selank is a tuftsin-derived heptapeptide with the sequence TKPRPGP. Both contain a C-terminal Pro-Gly-Pro sequence, but they are distinct molecular entities. N-acetyl variants and different salt forms are separate analytical articles; the identity, termini and counter-ion of each component must match the batch documentation.

Chemical properties and registry information

Registry identifiers refer to the individual molecular entities, not to the blend as a separately registered compound. Their applicability depends on the exact sequence, termini and material form; batch records take precedence over general literature identifiers.

Research background and published evidence

Published research

Semax literature includes peptide-identity and stability research, glial-cell gene-expression models, and biophysical studies of peptide–membrane interactions and metal coordination. Selank literature includes peptide identity, degradation, cellular and rodent gene-expression studies, and exploratory analysis of GABA-related pathways. These research contexts concern the individual peptides and do not establish findings for this combined catalogue formulation.

Current scientific understanding

The cited research background is predominantly mechanistic, cellular, animal-model and biophysical work. A definitive direct receptor mechanism is not established for either peptide. Shared sequence features do not establish interchangeable biological behaviour, and separate-compound observations do not demonstrate additive or synergistic effects. The effects and interactions of the Semax–Selank combination remain unestablished.

Formulation note

Published research mostly used other materials, formulations or routes rather than this exact nasal spray blend. Findings from injected or differently formulated material cannot be transferred to this nasal spray blend formulation. Differences in component identity, excipients, matrix and experimental context limit comparison. The catalogue format and stated strength do not establish equivalence to any published experimental material or suitability for human use.

Quality and testing

Quality information must be linked to a batch-specific certificate of analysis (CoA) for this exact two-compound presentation. Reports for separate Semax or Selank materials, other strengths or unrelated lots do not establish the identity, content or characteristics of this blend. Component-specific identity and content require corresponding analytical evidence.

Chromatographic area purity, individual peptide content, degradation products, counter-ion content, sterility, endotoxin and elemental impurities are distinct measurements. One result does not establish the others. Only tests documented in a visible, matching batch report should be regarded as available; stability or excipient composition must not be inferred from another product.

For laboratory research use only by qualified professionals. Not for human or veterinary use. No dosing directions are provided.